Estudo da expressão da proteína BCL-2 em mulheres com carcinoma ductal invasivo de mama. Correlação anatomopatólogica e da sobrevida
Carregando...
Data
2008-08-25
Autores
Nakamatu, Tereza [UNESP]
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
O câncer de mama é a afecção mais freqüente entre as mulheres em todo o mundo e com elevada taxa de mortalidade. Estímulos às pesquisas em várias direções para compreensão do comportamento biológico e possibilidade de melhor tratamento desta grave doença tem sido o desafio da ciência. Neste estudo foram avaliados a expressão da proteína Bcl-2, fatores anatomopatológicos (tamanho do tumor, comprometimento de linfonodo axilar e graduação histológica) e da sobrevida. Os fatores anatomopatológicos considerados foram: tamanho do tumor, metástases linfonodais. O fator biológico estudado é a proteína Bcl-2, analisado através da técnica imunohistoquímica. Quanto a sobrevida, as pacientes foram divididas em três grupos: sobrevida até 5 anos, de 5 a 10 anos e acima de 10 anos. Foram avaliados 117 mulheres com idade média de 50 a 59 anos que foram submetidas a tratameto cirúrgico, radioterápico e um dos três esquemas de tratamento de quimioterapia sistêmica: G1: 38 pacientes tratadas com CMF (Ciclofosfamida, Metotrexato e Fluoracil). G2: 35 pacientes tratadas com CEF (Ciclofosfamida , Epirrubicina e Fluoracil). G3: 44 pacientes tratadas com Tamoxifeno, 20 mg ao dia durante 5 anos. Os três grupos G1, G2 e G3 não apresentaram diferença estatísticamente significante quanto ao tamanho do tumor, grau histológico, expressão da proteína Bcl-2 e sobrevida. Não houve diferença estatísticamente significante entre a expressão da proteína Bcl-2 e sobrevida em nenhum dos três períodos avaliados. Não houve diferença estatísticamente significante entre o tamanho do tumor e proteína Bcl-2 em nenhum dos três períodos de sobrevida avaliados. Houve diferença estatísticamente significante entre grau histológico e expressão da proteína Resumo Bcl-2 nos períodos de 5 a 10 anos e acima de 10 anos. Houve diferença estatísticamente significante...
Breast cancer is the most common illness in women in the world and has a high mortality rate. Stimuli towards different angles of research to understand its biological behaviour and try to improve treatment for this serious disease have challenged science. This study evaluated Bcl-2 protein expression, anatomopathological factors (tumour size, axillary lymph node compromise, and histological grade), and survival. Anamotopathological factors considered were tumour size and lymph node metastases. The biological factor studied was Bcl- 2 protein, analyzed by immunohistochemistry. For survival, patients were divided into three groups: up to 5 years, 5 to 10 years, and more than 10 years survival. One hundred and seventeen women were evaluated; mean age was from 50 to 59 years, they were submitted to surgery, radiotherapy, and one of three systemic chemotherapy regimes: G1 – 38 patients treated with CMF (Cyclophosphamide, Metotrexate, and Fluoracyl). G2: 35 patients treated with CEF (Cyclophosphamide, Epirubicin, and Fluoracil). G3: 44 patients treated with 20mg/day Tamoxyphen for five years. The three groups did not present significant differences for tumour size, histology grade, Bcl-2 protein expression, or survival. There was no significant difference between Bcl-2 protein expression and survival in any of the three periods evaluated. There was no significant difference between tumour size and Bcl-2 in any of the three periods evaluated. There was significant difference between histological level and Bcl-2 protein expression in the 5-10 years and over 10 years periods. There was significant difference between axillary compromise and Bcl-2 protein expression in the more than 10 years period.
Breast cancer is the most common illness in women in the world and has a high mortality rate. Stimuli towards different angles of research to understand its biological behaviour and try to improve treatment for this serious disease have challenged science. This study evaluated Bcl-2 protein expression, anatomopathological factors (tumour size, axillary lymph node compromise, and histological grade), and survival. Anamotopathological factors considered were tumour size and lymph node metastases. The biological factor studied was Bcl- 2 protein, analyzed by immunohistochemistry. For survival, patients were divided into three groups: up to 5 years, 5 to 10 years, and more than 10 years survival. One hundred and seventeen women were evaluated; mean age was from 50 to 59 years, they were submitted to surgery, radiotherapy, and one of three systemic chemotherapy regimes: G1 – 38 patients treated with CMF (Cyclophosphamide, Metotrexate, and Fluoracyl). G2: 35 patients treated with CEF (Cyclophosphamide, Epirubicin, and Fluoracil). G3: 44 patients treated with 20mg/day Tamoxyphen for five years. The three groups did not present significant differences for tumour size, histology grade, Bcl-2 protein expression, or survival. There was no significant difference between Bcl-2 protein expression and survival in any of the three periods evaluated. There was no significant difference between tumour size and Bcl-2 in any of the three periods evaluated. There was significant difference between histological level and Bcl-2 protein expression in the 5-10 years and over 10 years periods. There was significant difference between axillary compromise and Bcl-2 protein expression in the more than 10 years period.
Descrição
Palavras-chave
Mamas - Cancer
Como citar
NAKAMATU, Tereza. Estudo da expressão da proteína BCL-2 em mulheres com carcinoma ductal invasivo de mama. Correlação anatomopatólogica e da sobrevida. 2008. 101 f. Dissertação (mestrado) - Universidade Estadual Paulista, Faculdade de Medicina de Botucatu, 2008.